Olga Kolman

Bio:

Olga Kolman is Head of US Emerging Portfolio Strategy at Servier Pharmaceuticals, where she brings deep U.S. market expertise to support global initiatives and strategy development. Since joining the company in 2022, she has led U.S. strategic input into business development evaluations, pipeline and lifecycle management programs, and global disease area strategy—helping to align scientific opportunities with commercial potential.

Prior to Servier, Olga led medical strategy and companion diagnostic development at Leica Biosystems (a Danaher company). She also served as Senior Director of Disease Area Portfolio Innovation at Biogen, where she oversaw strategy development for multiple therapeutic areas. Earlier in her career, she was Director of R&D Decision Support at Shire, leading portfolio strategy and prioritization for early-stage research and development. She began her career as a biopharma strategy consultant at Health Advances, specializing in oncology and rare diseases.

Olga holds an MD from Weill Cornell Medical College and completed her residency and fellowship in pathology at Massachusetts General Hospital. She lives in Boston with her husband and two sons and enjoys hiking and baking in her free time.